Delving into the Latest Updates on NXL-102 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Bacterial Infections

Originator Organization

Aventis Pharma SARL

Active Organization-

Inactive Organization

Novexel SAAventis Pharma SARL

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

We describe here the synthesis and biological evaluation of a series of benzo[b]naphthyridones, a new family of tricyclic antibacterial compounds that have a gram-positive spectrum of activity. RP60556A, one of the most potent of these compounds, is bactericidal against multiresistant cocci, especially multiresistant Staphylococcus aureus strains. Its physico-chemical and biological properties make it particularly suitable for topical antibacterial use.

100 Deals associated with NXL-102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bacterial Infections	Discovery	FR	Aventis Pharma SARL	-
Bacterial Infections	Discovery	FR	Aventis Pharma SARL	-
Bacterial Infections	Discovery	FR	Novexel SA	-
Bacterial Infections	Discovery	FR	Novexel SA	-